 ROCKVILLE, MD, Nov. 04, 2020 GLOBE NEWSWIRE -- MacroGenics, Inc. NASDAQ: MGNX, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced six clinical and preclinical abstracts related to acute myeloid leukemia AML and flotetuzumab, an investigational bispecific CD123 × CD3 DART molecule, and one abstract related to tebotelimab, an investigational bispecific PD-1 × LAG-3 DART molecule, to be presented at the 62nd American Society of Hematology ASH Annual Meeting Exposition, December 5-8, 2020. 